IGC Pharma, Inc. IGC

$0.18 -4.61% at last close
Market Cap$20.54 million
P/E Ratio—
Div Yield—
Volume509.4K
52-Week Range $0.08$0.45

Analyst Ratings

Consensus
Buy — 1 Buy · 0 Hold · 0 Sell (1 analysts)
Avg. Price Target
$6.00 (+3309.1% upside)

Full IGC forecast & analyst actions →

Key Stats

Today's Range
$0.17 – $0.19
50-Day Range
$0.08 – $0.30
52-Week Range
$0.08 – $0.45
Volume
509K shs
Average Volume
553K shs
Market Cap
$20.54 million
P/E Ratio
—
Dividend Yield
—

Short Interest

Short Interest
0.52%
Days to Cover
1.00

About IGC Pharma, Inc.

IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.

Sector
PHARMACEUTICAL PREPARATIONS
Employees
70
Exchange
XASE
Listed
2006-04-13

Related Stocks

Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.